AVN
MCID: AVS003
MIFTS: 42

Avascular Necrosis (AVN)

Categories: Bone diseases, Rare diseases

Aliases & Classifications for Avascular Necrosis

MalaCards integrated aliases for Avascular Necrosis:

Name: Avascular Necrosis 58 54
Avn 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare bone diseases


External Ids:

ICD10 via Orphanet 33 M87.0 M87.1 M87.2 more
Orphanet 58 ORPHA399164

Summaries for Avascular Necrosis

MalaCards based summary : Avascular Necrosis, also known as avn, is related to familial avascular necrosis of the femoral head and osteonecrosis. An important gene associated with Avascular Necrosis is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways are Mesenchymal Stem Cells and Lineage-specific Markers and Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and endothelial, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Wikipedia : 74 Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Related Diseases for Avascular Necrosis

Diseases in the Avascular Necrosis family:

Rare Hereditary Disease with Avascular Necrosis Secondary Avascular Necrosis
Primary Avascular Necrosis

Diseases related to Avascular Necrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 321, show less)
# Related Disease Score Top Affiliating Genes
1 familial avascular necrosis of the femoral head 34.5 TRPV4 COL2A1
2 osteonecrosis 32.8 COL2A1 BMP2 ABCB1
3 osteochondritis dissecans 30.4 COL2A1 BMP2
4 arthropathy 30.1 TRPV4 TNFRSF11A COL2A1
5 type ii collagen disorders 30.1 TRPV4 COL2A1
6 skeletal dysplasias 30.1 TRPV4 COL2A1
7 bone resorption disease 29.7 TNFRSF11A BMP2
8 bone disease 29.7 TNFRSF11A COL2A1 BMP2
9 scoliosis 29.2 TRPV4 TNFRSF11A COL2A1
10 avascular necrosis of femoral head, primary, 1 13.0
11 avascular necrosis of femoral head, primary, 2 12.7
12 idiopathic avascular necrosis 12.6
13 traumatic avascular necrosis 12.6
14 secondary avascular necrosis 12.5
15 primary avascular necrosis 12.5
16 avascular necrosis of genetic origin 12.4
17 secondary non-traumatic avascular necrosis 12.4
18 rare hereditary disease with avascular necrosis 12.4
19 legg-calve-perthes disease 12.3
20 dieterich's disease 11.7
21 kohler's disease 11.7
22 dyskeratosis congenita 11.7
23 osteochondrosis of the metatarsal bone 11.4
24 thiemann disease 11.3
25 arthrogryposis, perthes disease, and upward gaze palsy 11.3
26 dysbaric osteonecrosis 11.3
27 pr interval, variation in 11.3
28 sickle cell disease 10.7
29 systemic lupus erythematosus 10.7
30 lupus erythematosus 10.7
31 developmental dysplasia of the hip 1 10.6
32 slipped capital femoral epiphysis 10.6
33 osteoarthritis 10.6
34 alcohol dependence 10.5
35 sickle cell anemia 10.4
36 graft-versus-host disease 10.4
37 leukemia, acute lymphoblastic 10.4
38 gaucher's disease 10.4
39 vasculitis 10.4
40 osteoporosis 10.4
41 bone mineral density quantitative trait locus 8 10.4
42 bone mineral density quantitative trait locus 15 10.4
43 thalassemia 10.4
44 osteochondrosis 10.4
45 osteomyelitis 10.3
46 gout 10.3
47 alcohol use disorder 10.3
48 antiphospholipid syndrome 10.3
49 thrombophilia 10.3
50 septic arthritis 10.3
51 myeloid leukemia 10.3
52 bunion 10.3
53 hemoglobinopathy 10.3
54 47,xyy 10.3
55 kienbock's disease 10.3
56 chronic pain 10.3
57 gaucher disease, type i 10.2
58 immune deficiency disease 10.2
59 plica syndrome 10.2
60 acute chest syndrome 10.2
61 synovitis 10.2
62 chronic graft versus host disease 10.2
63 leukemia, chronic myeloid 10.2
64 beta-thalassemia 10.2
65 leukemia 10.2
66 vascular disease 10.2
67 cerebral palsy 10.2
68 severe acute respiratory syndrome 10.2
69 purpura 10.2
70 raynaud phenomenon 10.2
71 back pain 10.2
72 metatropic dysplasia 10.2 TRPV4 COL2A1
73 scleroderma, familial progressive 10.2
74 thrombophilia due to thrombin defect 10.2
75 alpha-thalassemia 10.2
76 exanthem 10.2
77 inflammatory bowel disease 10.2
78 lymphoma 10.2
79 frozen shoulder 10.2
80 thrombocytopenia 10.2
81 bursitis 10.2
82 systemic scleroderma 10.2
83 pustulosis of palm and sole 10.2
84 b-cell lymphoma 10.2
85 ulcerative colitis 10.2
86 psoriasis 10.2
87 rapidly involuting congenital hemangioma 10.2
88 brachyolmia 10.1 TRPV4 COL2A1
89 spondyloepiphyseal dysplasia with congenital joint dislocations 10.1 TRPV4 COL2A1
90 spondyloarthropathy 1 10.1
91 autoimmune disease 10.1
92 coxa vara 10.1
93 pemphigus vulgaris, familial 10.1
94 slipped femoral capital epiphyses 10.1
95 lymphoma, hodgkin, classic 10.1
96 myeloma, multiple 10.1
97 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
98 leukemia, acute lymphoblastic 3 10.1
99 deficiency anemia 10.1
100 colitis 10.1
101 dermatomyositis 10.1
102 brucellosis 10.1
103 disseminated intravascular coagulation 10.1
104 inflammatory spondylopathy 10.1
105 acute leukemia 10.1
106 hyperparathyroidism 10.1
107 glomerulonephritis 10.1
108 pituitary adenoma 10.1
109 adenoma 10.1
110 spondylitis 10.1
111 crohn's disease 10.1
112 pemphigus 10.1
113 fatty liver disease 10.1
114 acute graft versus host disease 10.1
115 osteonecrosis of the jaw 10.1
116 small cell cancer of the lung 10.1
117 celiac disease 1 10.1
118 small cell carcinoma 10.1
119 degenerative disc disease 10.1
120 acute myocardial infarction 10.1
121 alopecia 10.1
122 hip subluxation 10.1
123 spondyloepimetaphyseal dysplasia, matrilin-3 related 10.1 TRPV4 COL2A1
124 synovial chondromatosis 10.0 COL2A1 BMP2
125 polycystic kidney disease 2 with or without polycystic liver disease 10.0 TRPV4 NEK9
126 breast cancer 10.0
127 multiple sclerosis 10.0
128 hypercholesterolemia, familial, 1 10.0
129 endosteal hyperostosis, autosomal dominant 10.0
130 hypertriglyceridemia, familial 10.0
131 metachondromatosis 10.0
132 thrombocytopenic purpura, autoimmune 10.0
133 lymphoma, non-hodgkin, familial 10.0
134 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.0
135 kashin-beck disease 10.0
136 pain agnosia 10.0
137 rickets 10.0
138 chondrocalcinosis 10.0
139 clubfoot 10.0
140 otosclerosis 10.0
141 multiple epiphyseal dysplasia 10.0
142 leukostasis 10.0
143 childhood type dermatomyositis 10.0
144 thrombocytosis 10.0
145 testicular cancer 10.0
146 complex regional pain syndrome 10.0
147 liver cirrhosis 10.0
148 peripheral nervous system disease 10.0
149 hemolytic anemia 10.0
150 juvenile rheumatoid arthritis 10.0
151 neuroblastoma 10.0
152 arthritis 10.0
153 neuropathy 10.0
154 head injury 10.0
155 spinal cord injury 10.0
156 pik3ca-related overgrowth syndrome 10.0
157 overgrowth syndrome 10.0
158 dyssegmental dysplasia, silverman-handmaker type 10.0 COL2A1 BMP2
159 tympanosclerosis 10.0 COL2A1 BMP2
160 cartilage disease 10.0 COL2A1 BMP2
161 fibrochondrogenesis 10.0 COL2A1 BMP2
162 diastrophic dysplasia 10.0 COL2A1 BMP2
163 bone deterioration disease 9.9 COL2A1 BMP2
164 ischemic bone disease 9.9 COL2A1 BMP2
165 exostosis 9.9 COL2A1 BMP2
166 tooth resorption 9.9 TNFRSF11A BMP2
167 bone structure disease 9.9 COL2A1 BMP2
168 hair whorl 9.9
169 renal cell carcinoma, nonpapillary 9.9
170 leukemia, chronic lymphocytic 9.9
171 migraine with or without aura 1 9.9
172 dowling-degos disease 1 9.9
173 spondylolisthesis 9.9
174 talonavicular coalition 9.9
175 trichorhinophalangeal syndrome, type i 9.9
176 adrenocortical carcinoma, hereditary 9.9
177 buerger disease 9.9
178 pituitary adenoma 4, acth-secreting 9.9
179 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
180 familial mediterranean fever 9.9
181 osteogenic sarcoma 9.9
182 osteoid osteoma 9.9
183 periodontitis, chronic 9.9
184 pituitary hormone deficiency, combined, 2 9.9
185 dyskeratosis congenita, x-linked 9.9
186 leukemia, acute myeloid 9.9
187 intervertebral disc disease 9.9
188 cervical cancer 9.9
189 aneurysmal bone cysts 9.9
190 meningioma, radiation-induced 9.9
191 allergic rhinitis 9.9
192 meningioma, familial 9.9
193 coronary heart disease 1 9.9
194 psoriatic arthritis 9.9
195 asthma-related traits 2 9.9
196 granulomatosis with polyangiitis 9.9
197 intraocular pressure quantitative trait locus 9.9
198 kawasaki disease 9.9
199 acute promyelocytic leukemia 9.9
200 cholangitis, primary sclerosing 9.9
201 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
202 juvenile arthritis 9.9
203 adrenal cortical carcinoma 9.9
204 infective endocarditis 9.9
205 crohn's colitis 9.9
206 primary pigmented nodular adrenocortical disease 9.9
207 pollen allergy 9.9
208 childhood acute myeloid leukemia 9.9
209 fibrous dysplasia 9.9
210 mucolipidosis 9.9
211 endocarditis 9.9
212 osteomalacia 9.9
213 sarcoma 9.9
214 pituitary apoplexy 9.9
215 erysipelas 9.9
216 spinal meningioma 9.9
217 nephrotic syndrome 9.9
218 conn's syndrome 9.9
219 primary biliary cirrhosis 9.9
220 male infertility 9.9
221 pancytopenia 9.9
222 secondary hyperparathyroidism 9.9
223 renal osteodystrophy 9.9
224 acute cystitis 9.9
225 osteopetrosis 9.9
226 cholestasis 9.9
227 sick sinus syndrome 9.9
228 acute poststreptococcal glomerulonephritis 9.9
229 sclerosing cholangitis 9.9
230 hypothyroidism 9.9
231 limited scleroderma 9.9
232 thrombocytopenia due to platelet alloimmunization 9.9
233 ichthyosis 9.9
234 pericarditis 9.9
235 islet cell tumor 9.9
236 impotence 9.9
237 hepatitis c 9.9
238 hyperuricemia 9.9
239 rectum cancer 9.9
240 hyperostosis 9.9
241 myeloproliferative neoplasm 9.9
242 ankylosis 9.9
243 nocardiosis 9.9
244 relapsing-remitting multiple sclerosis 9.9
245 protein s deficiency 9.9
246 hemangioma 9.9
247 kidney cancer 9.9
248 acute pancreatitis 9.9
249 proctitis 9.9
250 lipid metabolism disorder 9.9
251 teratoma 9.9
252 cerebritis 9.9
253 mammary paget's disease 9.9
254 thrombophlebitis 9.9
255 adrenal cortical adenocarcinoma 9.9
256 liver disease 9.9
257 hyperglycemia 9.9
258 femoral neuropathy 9.9
259 myopathy 9.9
260 spindle cell sarcoma 9.9
261 secretory meningioma 9.9
262 lymphoplasmacyte-rich meningioma 9.9
263 brain edema 9.9
264 infertility 9.9
265 kidney disease 9.9
266 adult acute lymphocytic leukemia 9.9
267 bronchitis 9.9
268 reactive arthritis 9.9
269 connective tissue disease 9.9
270 diffuse idiopathic skeletal hyperostosis 9.9
271 spinal stenosis 9.9
272 acth-secreting pituitary adenoma 9.9
273 end stage renal disease 9.9
274 chronic kidney disease 9.9
275 cocaine abuse 9.9
276 myocarditis 9.9
277 periodontitis 9.9
278 cataract 9.9
279 chordoid meningioma 9.9
280 mucormycosis 9.9
281 lung disease 9.9
282 collagen disease 9.9
283 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.9
284 diabetes insipidus 9.9
285 cholangitis 9.9
286 lipid storage disease 9.9
287 pulmonary embolism 9.9
288 stomatitis 9.9
289 aphthous stomatitis 9.9
290 tenosynovitis 9.9
291 hypersensitivity vasculitis 9.9
292 trichorhinophalangeal syndrome 9.9
293 48,xyyy 9.9
294 bone marrow necrosis 9.9
295 catastrophic antiphospholipid syndrome 9.9
296 coccygodynia 9.9
297 congenital femoral deficiency 9.9
298 dwarfism 9.9
299 glucagonoma 9.9
300 homologous wasting disease 9.9
301 leukoplakia 9.9
302 oncogenic osteomalacia 9.9
303 retroperitoneal fibrosis 9.9
304 rheumatoid vasculitis 9.9
305 secondary adrenal insufficiency 9.9
306 ulcerative proctitis 9.9
307 aneurysm 9.9
308 anoxia 9.9
309 cerebral aneurysms 9.9
310 paraneoplastic syndromes 9.9
311 inflammatory myopathy with abundant macrophages 9.9
312 specific language disorder 9.9
313 solitary bone cyst 9.9
314 pediatric systemic lupus erythematosus 9.9
315 sensory peripheral neuropathy 9.9 TRPV4 ABCB1
316 bone development disease 9.8 COL2A1 BMP2
317 odontochondrodysplasia 9.7 TRPV4 COL2A1 BMP2
318 brachydactyly 9.7 TRPV4 COL2A1 BMP2
319 brittle bone disorder 9.7 COL2A1 BMP2
320 bone remodeling disease 9.6 TNFRSF11A BMP2
321 polycystic kidney disease 4 with or without polycystic liver disease 9.6 TRPV4 NEK9

Graphical network of the top 20 diseases related to Avascular Necrosis:



Diseases related to Avascular Necrosis

Symptoms & Phenotypes for Avascular Necrosis

MGI Mouse Phenotypes related to Avascular Necrosis:

45 (showing 4, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 ABCB1 BMP2 COL2A1 TNFRSF11A
2 homeostasis/metabolism MP:0005376 9.5 ABCB1 BMP2 COL2A1 NEK9 SREBF2 TNFRSF11A
3 hearing/vestibular/ear MP:0005377 9.46 ABCB1 BMP2 COL2A1 TRPV4
4 liver/biliary system MP:0005370 8.92 ABCB1 COL2A1 SREBF2 TNFRSF11A

Drugs & Therapeutics for Avascular Necrosis

Drugs for Avascular Necrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 266, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
7
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
8 Methylprednisolone Acetate Phase 4
9 Neuroprotective Agents Phase 4
10 Protective Agents Phase 4
11 Antioxidants Phase 4
12
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
13
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
14
leucovorin Approved Phase 3 58-05-9 6006 143
15
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
16
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
17
Pegaspargase Approved, Investigational Phase 3 130167-69-0
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Daunorubicin Approved Phase 3 20830-81-3 30323
20
Mercaptopurine Approved Phase 3 50-44-2 667490
21
Thioguanine Approved Phase 3 154-42-7 2723601
22
Idarubicin Approved Phase 3 58957-92-9 42890
23
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
24
Deflazacort Approved, Investigational Phase 2, Phase 3 14484-47-0
25
Zoledronic Acid Approved Phase 3 118072-93-8 68740
26
Denosumab Approved Phase 3 615258-40-7
27
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
30 Antimetabolites Phase 3
31 Calcium, Dietary Phase 3
32 Calciferol Phase 3
33 Anti-Infective Agents Phase 3
34 Hormone Antagonists Phase 3
35 Hormones Phase 3
36 Anti-Bacterial Agents Phase 3
37 Antibiotics, Antitubercular Phase 3
38 Ibandronic Acid Phase 3
39 Gastrointestinal Agents Phase 3
40 Vitamin B Complex Phase 3
41 Folic Acid Antagonists Phase 3
42 Folate Phase 3
43 Dermatologic Agents Phase 3
44 Anti-Inflammatory Agents Phase 3
45 Antirheumatic Agents Phase 3
46 Vitamin B9 Phase 3
47 Antineoplastic Agents, Hormonal Phase 3
48 Antiemetics Phase 3
49 Alkylating Agents Phase 3
50
Liposomal doxorubicin Phase 3 31703
51 Antiviral Agents Phase 3
52 Tubulin Modulators Phase 3
53 BB 1101 Phase 3
54 Antimitotic Agents Phase 3
55
asparaginase Phase 3
56 Immunologic Factors Phase 2, Phase 3
57 Immunosuppressive Agents Phase 2, Phase 3
58 Diphosphonates Phase 3
59 glucocorticoids Phase 3
60 Immunoglobulins Phase 3
61 Antibodies Phase 3
62 Antibodies, Monoclonal Phase 3
63
Calcium Nutraceutical Phase 3 7440-70-2 271
64
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
65
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
66
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
67
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
68
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
69
Lenograstim Approved, Investigational Phase 2 135968-09-1
70
Busulfan Approved, Investigational Phase 2 55-98-1 2478
71
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
72
alemtuzumab Approved, Investigational Phase 2 216503-57-0
73
Melphalan Approved Phase 2 148-82-3 460612 4053
74
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
75
Atorvastatin Approved Phase 2 134523-00-5 60823
76 Cytochrome P-450 Enzyme Inhibitors Phase 2
77 Cytochrome P-450 CYP3A Inhibitors Phase 2
78 Angiogenesis Inhibitors Phase 2
79 Interleukin-2 Phase 2
80 Pharmaceutical Solutions Phase 2
81 Antifungal Agents Phase 2
82 Adjuvants, Immunologic Phase 2
83 Thymoglobulin Phase 2
84 Calcineurin Inhibitors Phase 2
85 Antilymphocyte Serum Phase 2
86 Antineoplastic Agents, Immunological Phase 2
87 Hypolipidemic Agents Phase 2
88 Anticholesteremic Agents Phase 2
89 Lipid Regulating Agents Phase 2
90 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
91
Acetylcholine Approved, Investigational Phase 1 51-84-3 187
92 Cholinergic Agents Phase 1
93 Vasodilator Agents Phase 1
94 omega-N-Methylarginine Phase 1
95 Sildenafil Citrate Phase 1 171599-83-0
96 Neurotransmitter Agents Phase 1
97
rituximab Approved 174722-31-7 10201696
98
Cefprozil Approved Early Phase 1 92665-29-7 5281006
99
Tazobactam Approved Early Phase 1 89786-04-9 123630
100
Penicillin G Approved, Vet_approved Early Phase 1 61-33-6 5904
101
Clarithromycin Approved Early Phase 1 81103-11-9 84029
102
Erythromycin Approved, Investigational, Vet_approved Early Phase 1 114-07-8 12560 441411
103
Cefepime Approved, Investigational Early Phase 1 88040-23-7 5479537
104
Chloramphenicol succinate Approved Early Phase 1 3544-94-3
105
Cefoperazone Approved, Investigational Early Phase 1 62893-19-0 44185
106
Netilmicin Approved, Investigational Early Phase 1 56391-56-1 6857423 441306
107
Dicloxacillin Approved, Investigational, Vet_approved Early Phase 1 3116-76-5 18381
108
Clavulanate Approved, Vet_approved Early Phase 1 58001-44-8 5280980
109
Cefonicid Approved, Investigational Early Phase 1 61270-58-4 43594 43592
110
Ceftibuten Approved, Investigational Early Phase 1 97519-39-6 5282242 5282241
111
Cefotetan Approved Early Phase 1 69712-56-7 50614
112
Gatifloxacin Approved, Investigational Early Phase 1 112811-59-3 5379
113
Colistin Approved Early Phase 1 1264-72-8, 1066-17-7 5311054
114
Penicillin V Approved, Vet_approved Early Phase 1 87-08-1 6869
115
Ceftriaxone Approved Early Phase 1 73384-59-5 5361919 5479530
116
Cefmetazole Approved, Investigational Early Phase 1 56796-20-4 42008
117
Tetracycline Approved, Vet_approved Early Phase 1 60-54-8 5353990
118
Neomycin Approved, Vet_approved Early Phase 1 1404-04-2 8378
119
Cefpodoxime Approved, Vet_approved Early Phase 1 80210-62-4, 82619-04-3 6335986
120
Paromomycin Approved, Investigational Early Phase 1 7542-37-2, 1263-89-4 165580
121
Ciprofloxacin Approved, Investigational Early Phase 1 85721-33-1 2764
122
Methenamine Approved, Vet_approved Early Phase 1 100-97-0 4101
123
Lincomycin Approved, Vet_approved Early Phase 1 154-21-2 656509
124
Mezlocillin Approved, Investigational Early Phase 1 51481-65-3 656511
125
Cefamandole nafate Approved Early Phase 1 57268-80-1
126
Amoxicillin Approved, Vet_approved Early Phase 1 26787-78-0 33613
127
Dalfopristin Approved Early Phase 1 112362-50-2 6435782 21943991
128
Sulfacetamide Approved Early Phase 1 144-80-9 5320
129
Cefixime Approved, Investigational Early Phase 1 79350-37-1 5362065 54362
130
Sulbactam Approved Early Phase 1 68373-14-8
131
Ceftazidime Approved Early Phase 1 72558-82-8, 78439-06-2 5481173